Uncover key drivers, emerging technologies, and competitive movements shaping the cancer gene therapy market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Market Size Of The Cancer Gene Therapy Industry By 2029?

The cancer gene therapy market size has seen substantial growth recently. It is anticipated to expand from $3.61 billion in 2024 to $4.21 billion in 2025, at a compound annual growth rate (CAGR) of 16.6%. The historical expansion of this market can be attributed to heightened awareness of oncovirus-related cancers, an uptick in collaborations between biotechnology firms and academic bodies, increased clinical trial participation for early-phase gene therapies, a rising demand for ex vivo modified cell therapies, and a notable rise in strategic licensing deals for gene therapy platforms.

The cancer gene therapy market size is expected to undergo substantial growth over the next few years. It is projected to expand to $7.67 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 16.2%. This expansion during the forecast period can be attributed to an increased focus on non-viral delivery systems, wider availability of companion diagnostics, rising interest in off-the-shelf allogeneic cell therapies, the increasing reach of contract development & manufacturing organizations (CDMOs), and advancements in synthetic biology that enable customizable gene circuits. Key trends anticipated in this period include developments in non-viral gene delivery platforms, sophisticated manufacturing automation for gene therapy production, the creation of synthetic promoters for cancer-specific expression, innovations in intratumoral gene therapy administration, and the development of multiplexed gene modulation strategies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

Which Factors Are Steering Growth In The Cancer Gene Therapy Market?

The rising occurrence of cancer is anticipated to drive expansion in the cancer gene therapy market in the future. Cancer is defined as an illness marked by the uncontrolled proliferation of atypical cells, capable of invading and spreading throughout the body, originating in diverse tissues and organs, and categorized by its cell or tissue of origin. The number of cancer cases is escalating, primarily attributed to extended life expectancy, given that the likelihood of developing cancer increases with age. Cancer gene therapy addresses cancer by either altering or substituting defective genes to halt the proliferation of cancer cells or to boost the immune system’s capacity to eliminate them. As an illustration, Macmillan Cancer Support, an organization based in the UK, reported in August 2024 that over 3 million individuals in the UK are currently living with cancer. This number is forecasted to climb to 3.5 million by 2025, 4 million by 2030, and reach 5.3 million by 2040. Consequently, the rising incidence of cancer is a key factor fueling the expansion of the cancer gene therapy market.

Which Segment Accounts For The Largest Share In The Cancer Gene Therapy Market?

The cancer gene therapy market covered in this report is segmented

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

Which Long-Term Trends Will Play A Crucial Role In The Cancer Gene Therapy Market?

Leading companies in the cancer gene therapy market are concentrating on developing advanced treatments, such as CAR-T cell therapy, to enhance therapeutic precision, improve patient outcomes, and more effectively target cancer cells while minimizing harm to healthy tissues. CAR-T therapy is an advanced form of immunotherapy where a patient’s immune cells are engineered with special receptors to better detect and destroy cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), which is the country’s first indigenously developed CAR-T cell therapy for cancer. Specifically formulated to treat B-cell lymphomas and leukemias, NexCAR19 functions by reprogramming a patient’s own T cells to identify and eliminate malignant cells. Built upon advanced chimeric antigen receptor (CAR) technology, this therapy is domestically manufactured, thereby increasing its affordability and accessibility compared to imported choices. This launch signifies a crucial milestone for India’s entry into the global cancer gene therapy space, showcasing notable progress in domestic innovation and personalized cancer treatment.

Who Are The Dominant Players In The Cancer Gene Therapy Market Today?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

What Regional Factors Are Accelerating Growth In The Cancer Gene Therapy Market?

North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2025, By The Business Research Company

Mortgage Lender Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mortgage-lender-global-market-report

Home Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/home-insurance-global-market-report

Mortgage Brokerage Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/mortgage-brokerage-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model